

Canadian Society of Allergy and Clinical Immunology

## Annual Scientific Virtual Meeting



October 22 to 24, 2020

**PRELIMINARY PROGRAM**

**We are very pleased to host our 75<sup>th</sup> meeting of the Canadian Society of Allergy and Clinical Immunology.** The CSACI Annual Scientific Meeting (ASM) is a highly anticipated event each year and is our Society's flagship event. It serves as a chance to network with colleagues, exchange ideas, and gain knowledge, while also socializing and renewing friendships. The health and safety of our members, our patients, staff, family and friends are our highest priority.


Due to the pandemic, the CSACI Board of Directors, along with the ASM Program and CPD Committees, have made the decision to convert the ASM planned for October to a **virtual platform**.

Our program will showcase both live streaming and recorded components. By converting to a virtual meeting, we will be able to reach those who could not have attended our in-person meeting in Ottawa. Our virtual meeting will provide our delegates with exceptional CPD, as well as the ability to share scientific news and best practices together...all without leaving home. It will feature a compelling array of sessions including Virtual talks, a Pro/Con debate and interactive workshops, as well as a virtual exhibit hall, which will reach audiences across Canada, the USA and beyond.

Have a great meeting!

Dr. Harold Kim  
CSACI President

Dr. David Fischer  
2020 Program Chair



## 2020 ANNUAL SCIENTIFIC MEETING

### PLANNING COMMITTEE

Dr. Harold Kim, CSACI President  
Dr. David Fischer, 2020 ASM Chair, CPD Committee  
Dr. Tim Vander Leek, CSACI Vice President  
Dr. Anne Ellis, CSACI Treasurer, FIT Bowl Chair  
Dr. Lori Connors, CPD Committee Chair, CSACI Board

Dr. Catherine Biggs, Abstract Co-Chair  
Dr. Scott Cameron, 2020 Program Committee, CPD Com.  
Dr. Edmond Chan, CSACI Board  
Dr. Victoria Cook, 2020 Program Committee, CPD Com.  
Dr. Keelia Farrell, FIT Representative  
Dr. Charles Frankish, 2020 Program Committee, CPD Com.  
Dr. Kyla Hildebrand, CSACI Board  
Dr. Samira Jeimy, Abstract Co-Chair  
Dr. Sandy Kapur, 2020 Program Committee  
Dr. Elana Lavine, Pediatric Section Advisor  
Dr. Doug Mack, CSACI Board  
Dr. Christine McCusker, CSACI Board  
Dr. Beata Derfalvi, Immunology Section Advisor  
Dr. Andy O'Keefe, Asthma Section Advisor  
Dr. Jackie Quirt, Rhino-sinusitis Section Advisor  
Dr. Elinor Simons, Abstract Co-Chair  
Dr. Julia Upton, Anaphylaxis and Food Allergy Section Advisor  
Dr. Hari Vliagoftis, CSACI Board and Abstract Co-Chair  
Dr. Wade Watson, 2020 Program Committee, CPD Com.

Ms. Louise Tremblay, Executive Director  
Ms. Alexi Campbell, Manager  
Ms. Jasmin Lidington, Associate Executive Director

### PROGRAM OBJECTIVES

The CSACI Annual Scientific Meeting's main objective is to provide current information about the diagnosis, treatment and management for conditions related to allergy, asthma and immunology. This meeting is a setting for interdisciplinary exchange among professionals and provides an excellent opportunity for participants to interact virtually with colleagues and experts in the field. By participating in this conference, attendees can expect to evaluate new trends, techniques, therapies and diagnostic procedures in allergy, asthma and immunology.

- Maintain competence on a wide variety of up-to-date topics in Clinical Immunology and Allergy
- Discuss hot new topics (both published and un-published) that have arisen since the last CSACI meeting
- Establish a network of allergy and immunology colleagues from both community and university settings.
- Promote Clinical Immunology and Allergy as a specialty to our fellows-in-training, trainees and medical students.

### WHY YOU SHOULD ATTEND!

As the premier meeting of the allergy, asthma and immunology community, this conference provides several unique and engaging educational opportunities for the participant – you can:

- Interact virtually with an impressive faculty of Canadian and international speakers;
- Network virtually with colleagues across settings and disciplines;
- Translate scientific discoveries into your practice;
- Learn about policy issues that directly affect you;
- Raise questions, debate the issues, plan follow-up studies, and discuss results;
- Discuss your own research and observations;
- Meet virtually with poster presenters to learn about their research objectives; and
- Visit the exhibit hall featuring products and services specifically designed for professionals in allergy, asthma and immunology.

### TARGET AUDIENCE

The CSACI Annual Scientific meeting is intended for clinicians, researchers, trainees/students, and allied health professionals involved in research, treatment and management of diseases in allergy, asthma and immunology.

### EVALUATIONS

Delegates can provide feedback on Annual Meeting Sessions they attend by using the Annual Meeting app or by visiting the CSACI website.

#### CSACI Mission:

***The Canadian Society of Allergy & Clinical Immunology advances allergy, asthma, and immunology knowledge to optimize patient care across Canada.***

#### CSACI Vision:

***The leading expertise for care of people with allergic and immunologic disease.  
Striving for prevention and cure.***

## ANNUAL GENERAL MEETING

All CSACI members are invited to attend the CSACI and CAAIF AGMs

**DATE TO BE CONFIRMED – WILL BE HELD ON SEPARATE DATE AND TIME**

**Participants will be eligible to win a prize!**

---

## ACCREDITATION - (Section 1 & Section 3)

This event is an accredited group learning activity (Section 1 & Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Please refer to the final program for accredited sessions.

### ***AMA PRA Category 1 Credit™***

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credits to AMA credits can be found at:

[www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

### ***CERTIFICATE OF ATTENDANCE***

All participating delegates will receive an email containing their “Certificate of Attendance” following the meeting.

## PROGRAM CHANGES AND CANCELLATIONS

Please note: The CSACI reserves the right to substitute faculty or to cancel or reschedule sessions because of low enrollment or other unforeseen circumstances.

## DISCLOSURE

Faculty and Moderator Disclosure:

Current CME guidelines state that participants should be aware of any affiliation or financial interest that could affect the speaker’s presentation(s). Faculty and moderators have completed conflict of interest declarations and those potential conflicts will be listed in the announced at the beginning of each session.

The intent of this disclosure requirement is not to prevent a speaker with a conflict of interest from making a presentation but to make known the relationship, in advance, to the audience. It is intended that any conflict be openly identified so that with full disclosure of the facts, attendees may form their own judgments about the presentation.

In addition, all members of the annual scientific program committee have also completed their declaration and have announced at each teleconference or meeting any financial interest in commercial organizations that may have a direct or indirect interest in the subject matter of his/her presentation. A “financial interest” may include, but is not limited to, being a direct shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may be holding a position on an advisory committee or some other role of benefit to a sponsoring organization.

## DISCLAIMER

The material presented at this meeting represents the opinion of the speakers and not the views of the CSACI. Attendees participating in this medical education program do so with full knowledge that they waive any claim they may have against the CSACI for reliance on any information presented during these educational activities. The CSACI does not guarantee, warrant or endorse any commercial products or services.

## VISIT OUR 2020 SPONSORS AND EXHIBITORS IN THE EXHIBIT HALL

The CSACI meeting has proven to be a great opportunity for a collegial interchange of ideas and product information between physicians and our corporate partners. The exhibiting companies and organizations will provide you with the latest information on products and services available to physicians, researchers and allied health professionals in the field of allergy/immunology.

---



Want to win a gift card but  
tired of filling out the  
exhibitor passport?

The CSACI Trivia Game

...stay tuned for more details.

---

DON'T FORGET TO FOLLOW US ON TWITTER



Use **#CSACI2020** when you tweet  
to participate in virtual  
conversations & share what you're  
learning with your colleagues



**CSACI PROGRAM**  
**THURSDAY, OCTOBER 22, 2020**

|                  |  |
|------------------|--|
| <b>1000-1200</b> | <b>NREP MEETING (CLOSED)</b>   |
| <b>1010-1315</b> | <b>FIT SYMPOSIUM WORKSHOP, LUNCH AND ELECTIONS (CLOSED)</b>  |
| <b>0930-1010</b> | <b>BREAKFAST AND ORIENTATION</b>   |
| <b>1010-1045</b> | <b>SESSION 1: TRANSITION TO PRACTICE</b>   |
| <b>1045-1115</b> | <b>BREAK</b>   |
| <b>1115-1200</b> | <b>SESSION 2: ORAL FOOD CHALLENGES IN THE COMMUNITY</b>  |
| <b>1200-1230</b> | <b>VIRTUAL LUNCH</b>   |
| <b>1230-1250</b> | <b>ELECTIONS</b>   |
| <b>1250-1315</b> | <b>SESSION 3: MAST CELL DISORDERS</b>  |
| <b>1330-1600</b> | <b>IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY*</b><br><b>*PLEASE NOTE THAT THIS SYMPOSIUM IS FREE OF CHARGE HOWEVER IF YOU WOULD LIKE TO ATTEND THE CSACI VIRTUAL CONFERENCE, YOU MUST PAY A REGISTRATION FEE AS PER YOUR STATUS.</b>   |
| <b>1900-1915</b> | <b>OPENING REMARKS BY DR. HAROLD KIM AND DR. DAVID FISCHER</b>   |
| <b>1915-2000</b> | <b>CO-DEVELOPED DINNER</b><br><b>CO-SPONSORED: SANOFI GENZYME</b><br><b>MODERATORS: DR. DAVID FISCHER AND DR. PAUL KEITH</b><br><b>1915-1945 SPEAKER: DR. TANYA LAIDLAW, BOSTON, MA</b><br><b>TOPIC: ADVANCES IN THE TREATMENT OF NASAL POLYPOSIS</b><br><b>OBJECTIVES: By the end of this session participants will be able to:</b><br><b>1. Define patient population that may benefit from treatment advances for nasal polyposis</b><br><b>2. Compare and contrast current standard of care for nasal polyposis with biologics</b> |
| <b>1945-2000</b> | <b>DISCUSSION PERIOD</b>   |

**FRIDAY, OCTOBER 23, 2020**

**PLEASE NOTE THAT FOOD COUPONS WILL BE SENT TO REGISTERED PARTICIPANTS  
(PRIOR TO THE VIRTUAL MEETING)**

**0900-0955**

**CO-DEVELOPED BREAKFAST**

**CO-SPONSORED: MEDEXUS**

**MODERATORS: DR. DOUG MACK AND DR. REBECCA PRATT**

**0925-0945 SPEAKER: DR. ZAINAB ABDURRHAMAN, TORONTO, ON**

**TOPIC: AN APPROACH TO THE DIAGNOSIS AND MANAGEMENT OF**

**GENERALIZED PRURITUS**

**OBJECTIVES: By the end of this session participants will be able to:**

- 1. Describe pathophysiology of pruritus**
- 2. Summarize appropriate diagnostic evaluation for pruritus**
- 3. Compose a treatment plan for a patient presenting with generalized pruritus (including CanMEDs Communicator role)**

**0945-0955 DISCUSSION PERIOD**

**1000-1050**

**PLENARY SESSION I – FOOD ALLERGY**

**MODERATORS: DR. JULIA UPTON AND DR. VY KIM**

**1000-1020 SPEAKER: DR. RUCHI GUPTA, CHICAGO, ILLINOIS**

**TOPIC: DOES FOOD ALLERGY DISPROPORTIONATELY AFFECT PARTICULAR RACES AND ETHNICITIES?**

**OBJECTIVES: By the end of this session participants will be able to:**

- 1. Summarize existing data on food allergy and race/ethnicity**
- 2. Consider conscious and unconscious bias in management of food allergy (CanMEDs advocacy role)**

**1020-1040 SPEAKER: DR. SUSAN WASERMAN, HAMILTON, ON**

**TOPIC: REVIEW OF NEW CANADIAN/WORLD ANAPHYLAXIS IN SCHOOLS GUIDELINES**

**OBJECTIVES: By the end of this session participants will be able to:**

- 1. Compare Canadian and World anaphylaxis in schools' guidelines**
- 2. Explain implementation plan for Canadian anaphylaxis in schools' guidelines (CanMEDs advocacy role)**

**1040-1050 DISCUSSION PERIOD**

**1050-1100**

**VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)**

## FRIDAY, OCTOBER 23, 2020

- 1100-1150**            **PLENARY SESSION II – PRACTICAL MANAGEMENT OF IMMUNE DISEASES**  
**MODERATORS: DR. KYLA HILDEBRAND AND DR. GINA LACUESTA**  
**1100-1120**    **SPEAKER: DR. HILARY LONGHURST, UK**  
**TOPIC: HAE GUIDELINES DIAGNOSIS AND MANAGEMENT WITH AND WITHOUT COVID-19**  
**OBJECTIVES: By the end of this session participants will be able to:**  
**1. Summarize current HAE guidelines for all types of HAE**  
**2. Explain modifications in HAE management due to COVID-19**
- 1120-1140**    **SPEAKER: DR. ANNE PHAM-HUY, OTTAWA, ON**  
**TOPIC: TO VACCINATE OR NOT TO VACCINATE: WHAT IS ROLE FOR VACCINATION IN PRIMARY AND SECONDARY IMMUNE DEFICIENCIES**  
**OBJECTIVES: By the end of this session participants will be able to:**  
**1. Specify when vaccines are contraindicated in PID and SID**  
**2. Describe when to vaccinate in PID and SID**
- 1140-1150**    **DISCUSSION PERIOD**
- 1150-1210**            **CSACI AWARDS PRESENTATIONS AND OTHER CSACI NEWS**
- 1210-1300**            **CO-DEVELOPED LUNCH**  
**CO-SPONSORED BY MERCK**  
**MODERATORS: DR. JACKIE QUIRT AND DR. LORI CONNORS**  
**1230-1250**    **SPEAKER: DR. JACLYN SMITH, MANCHESTER, UK**  
**TOPIC: ADVANCES IN COUGH RESEARCH**  
**OBJECTIVES: By the end of this session participants will be able to:**  
**1. Define chronic cough**  
**2. Explain current diagnostic approach to chronic cough**  
**3. Compare current treatments and new treatment advances in chronic cough**
- 1250-1300**    **DISCUSSION PERIOD**



## FRIDAY, OCTOBER 23, 2020

- 1305-1355** KEYNOTE PRESENTATION – IMMUNOLOGY OF COVID-19  
MODERATORS: DR. HAROLD KIM AND DR. DAVID FISCHER  
1305-1325 SPEAKER: DR. CATHERINE BIGGS, VANCOUVER, BC  
TOPIC: MULTI-INFLAMMATORY RESPONSE SYNDROME IN COVID-19  
OBJECTIVES: By the end of this session participants will be able to:
1. Define multi-inflammatory response syndrome (MIRS)
  2. Discuss current Canadian and worldwide data on MIRS
- 1325-1345 SPEAKER: DR. SCOTT HALPERIN, HALIFAX, NS  
TOPIC: THE RACE FOR A COVID-19 VACCINE  
OBJECTIVES: By the end of this session participants will be able to:
1. Summarize vaccine development approach in Canada
  2. Explain COVID-19 vaccine development approach
- 1345-1355 DISCUSSION PERIOD
- 1355-1405** VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)
- 1405-1455** PLENARY SESSION III – Update in Peanut/Nut Allergies  
MODERATORS: DR. TIM VANDER LEEK AND DR. EDMOND CHAN  
1405-1425 SPEAKER: DR. HELEN BROUGH, LONDON, UK  
TOPIC: WHAT WE'VE LEARNED FROM THE PRO-NUTS STUDY ABOUT INTRODUCTION OF MULTIPLE NUTS AND SEEDS VIA CHALLENGES  
OBJECTIVES: By the end of this session participants will be able to:
1. Describe approach to multi-food oral challenges
  2. Explain Pro-Nuts study results and implications on clinical care
- 1425-1445 SPEAKER: DR. MARCUS SHAKER, HANOVER, NH  
TOPIC: TO BE CONFIRMED  
OBJECTIVES: By the end of this session participants will be able to:
- 1.
  - 2.
- 1445-1455 DISCUSSION PERIOD
- 1455-1500** SPEAKER AWARDS PRESENTATION

## FRIDAY, OCTOBER 23, 2020

1500-1640

### PLENARY SESSION IV – SECTION 3 CONCURRENT SESSIONS (CHOOSE YOUR TIMES AND TOPICS)

|           |   |
|-----------|---|
| 1500-1530 | <b>ORAL IMMUNOTHERAPY PRACTICAL MANAGEMENT</b><br><b>SPEAKERS: DR. VICTORIA COOK, DR. SCOTT CAMERON</b><br><b>OBJECTIVES: By the end of this session participants will be able to:</b> <ol style="list-style-type: none"> <li>1. Perform OIT in an outpatient clinic environment</li> <li>2. Manage side effects and reactions in OIT</li> </ol>  |
| 1535-1605 |   |
| 1610-1640 |   |
| 1500-1530 | <b>SCIT/SLIT Challenging CASE</b><br><b>SPEAKERS: DR. SAMIRA JEIMY, DR. BILL MOOTE</b><br><b>OBJECTIVES: By the end of this session participants will be able to:</b> <ol style="list-style-type: none"> <li>1. Manage complex SCIT/SLIT cases</li> <li>2. Obtain informed consent for SCIT/SLIT (CanMEDs Communicator role)</li> </ol>   |
| 1535-1605 |   |
| 1610-1640 |   |
| 1500-1530 | <b>MANAGING PSYCHOSOCIAL ASPECTS OF CARE IN ALLERGY/IMMUNOLOGY</b><br><b>SPEAKERS: DR. LORI CONNORS, DR. WADE WATSON</b><br><b>OBJECTIVES: By the end of this session participants will be able to:</b> <ol style="list-style-type: none"> <li>1. Work in intra and inter-professional teams to manage complex allergy/immunology patients (CanMEDs Collaborator and Leader role)</li> <li>2. Discuss psychosocial aspects of care in allergy/immunology (CanMEDs Communicator role)</li> </ol> |
| 1535-1605 |   |
| 1610-1640 |   |

## FRIDAY, OCTOBER 23, 2020

1500-1610

### CONCURRENT TALK – BASIC SCIENCE - "NEURO-IMMUNE INTERACTIONS IN ALLERGY"

*There is clear evidence that allergic inflammation involves constant cross-talk between immune cells and the nervous systems. Mediators, including cytokines, released by immune cells can modulate peripheral and central nervous system function, in turn altering neural control of inflammation and influencing the development and severity of allergic disease. In this session we will discuss some of these mechanisms"*

**MODERATOR: DR. HARISSIOS VLIAGOFTIS**

**OBJECTIVES: By the end of this session participants will be able to:**

1. Explain cross-talk between immune cells and the nervous system
2. Discuss mechanisms of neuro-immune interactions in allergy and immunology

1500-1515

**SPEAKER: DR. PAUL FORSYTH**

**TOPIC: BRAIN-GUT INTERACTIONS IN ALLERGY: ROLE OF THE MICROBIOME**

1515-1520

**DISCUSSION PERIOD**

1520-1535

**SPEAKER: DR. THOMAS RITZ**

**TOPIC: BRAIN-LUNG INTERACTIONS IN ALLERGY**

1535-1540

**DISCUSSION PERIOD**

1540-1555

**SPEAKER: DR. SEBASTIEN TALBOT**

**TOPIC: THE ROLE OF NOCICEPTORS IN ASTHMA**

1555-1600

**DISCUSSION PERIOD**

1600-1655

**VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA**

1700-1800

**FIT BOWL**

**MODERATORS: DR. ANNE ELLIS AND DR. CHARLES FRANKISH**

**OBJECTIVES: By the end of this session participants will be able to:**

1. Review interesting facts in allergy and immunology

## SATURDAY, OCTOBER 24, 2020

0830-0900

VIRTUAL YOGA SESSION

0900-0955

CO-DEVELOPED BREAKFAST AND  
CO-SPONSORED BY ALK

MODERATORS: DR. MARY MCHENRY AND DR. KYLA HILDEBRAND

0925-0945 SPEAKER: DR. ANNE ELLIS, KINGSTON, ON

TOPIC: ADVANCES IN SLIT IN 2020

OBJECTIVES: By the end of this session participants will be able to:

1. Analyze data on safety and efficacy of SLIT
2. Discuss therapeutic advances in SLIT

0945-0955 DISCUSSION PERIOD

1000-1050

PLENARY SESSION V - ASTHMA PLENARY: GINA GUIDELINES

MODERATORS: DR. ANDREW O'KEEFE AND DR. ELANA LAVINE

1000-1020 SPEAKER: DR. DIANNE LOUGHEED, KINGSTON, ON

TOPIC: COMPARING CTS GUIDELINES TO GINA GUIDELINES

OBJECTIVES: By the end of this session participants will be able to:

1. Summarize CTA and GINA guidelines
2. Compare and contrasts CTS guidelines with GINA guidelines

1020-1040 SPEAKER: DR CONNIE YANG, Vancouver, BC

TOPIC: PEDIATRIC IMPLICATIONS OF GINA GUIDELINES

OBJECTIVES: By the end of this session participants will be able to:

1. Explain implications on GINA guidelines on the pediatric population
2. Discuss gaps in evidence that may impact implementation of GINA guidelines in pediatrics (CanMEDs Scholar role)

1040-1050 DISCUSSION PERIOD

## SATURDAY, OCTOBER 24, 2020

**1050-1100** VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)

**1100-1210** PLENARY SESSION VI – CONCURRENT SESSIONS

| FOOD ALLERGY- OIT SESSIONS   | IMMUNOLOGY SESSIONS   |
|--|---|
| <p><b>1100-1120</b><br/> <b>MODERATORS: DR. SANDY KAPUR AND DR. ELISSA ABRAMS</b><br/> <b>SPEAKERS: DRS. EDMOND CHAN AND PHILIPPE BÉGIN, VANCOUVER, BC AND MONTREAL, QC</b><br/> <b>TOPIC: NEW CANADIAN OIT GUIDELINES</b><br/> <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Describe Canadian OIT guidelines</li> <li>2. Evaluate guidelines and whether you will incorporate them into your practice</li> </ol> | <p><b>1100-1120</b><br/> <b>MODERATORS: DR. CHRISTINE MCCUSKER AND DR. BEATA DERFALVI</b><br/> <b>SPEAKER: DR. TROY TORGERSON</b><br/> <b>TOPIC: IMMUNE DYSREGULATION/ AUTOIMMUNITY IN INBORN ERRORS OF IMMUNITY</b><br/> <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Define immune dysregulation in inborn errors of immunity</li> <li>2. Develop an approach to diagnosis and management of immune dysregulation</li> </ol> |
| <b>1120-1130 Discussion Period</b>   | <b>1120-1130 Discussion Period</b>  |
| <p><b>1130-1150</b><br/> <b>SPEAKER: DR. HAROLD KIM, KITCHENER, ON</b><br/> <b>TOPIC: WHAT IS THERE TO BE DONE ABOUT THE BILLING ISSUES IN OIT IN CANADA</b><br/> <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Compare and contrast current billing structures for OIT across Canada</li> <li>2. Advocate for improved access to OIT for patients (CanMEDs advocacy role)</li> </ol>                              | <p><b>1130-1150</b><br/> <b>SPEAKER: DR. STUART TURVEY, VANCOUVER, BC</b><br/> <b>TOPIC: GERMLINE CBM-OPATHIES: FROM IMMUNODEFICIENCY TO ATOPY</b><br/> <b>OBJECTIVES: By the end of this session participants will be able to:</b></p> <ol style="list-style-type: none"> <li>1. Define germline CBM-opathies</li> <li>2. Summarize clinical phenotypes of germline CBM-opathies</li> </ol>  |
| <b>1150-1210 DISCUSSION PERIOD</b>   | <b>1150-1210 DISCUSSION PERIOD</b>  |

**1210-1255** CO-DEVELOPED LUNCH  
 CO-SPONSORED BY GLAXOSMITHKLINE  
 MODERATORS: DR. REZA ALIZADEFHAR AND DR. MICHAEL FEIN  
**1230-1250** SPEAKER: Dr. Richard Leigh, Calgary, AB  
 TOPIC: BIOLOGICS GINA-ASTHMA  
 OBJECTIVES: By the end of this session participants will be able to:

1. Classify asthma by phenotype
2. Describe classes of biologics for asthma
3. Discuss GINA guidelines as they pertain to biologics in asthma

**1250-1300** DISCUSSION PERIOD

## SATURDAY, OCTOBER 24, 2020

- 1300-1330**      **PRO-CON DEBATE**  
**TOPIC: BIRT: BUDESONIDE/FORMOTEROL AS NEEDED IS A BETTER THERAPEUTIC APPROACH TO MILD ASTHMA THAN REGULAR USE OF INHALED CORTICOSTEROIDS**  
**MODERATORS: DR. ALLAN BECKER AND DR. SUSAN WASERMAN**  
**SPEAKERS:**  
**1300-1310      PRO: DR CHARLES CHAN, TORONTO, ON**  
**1310-1320      CON: DR. MEYER BALTER, TORONTO, ON**  
**OBJECTIVES: By the end of this session participants will be able to:**  
**1. Compare and contrast data on budesonide/formoterol as needed and regular use of inhaled corticosteroids**
- 1330-1340      DISCUSSION PERIOD**
- 1340-1350**      **VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)**
- 1350-1500**      **ORAL ABSTRACT QUICK SNAPPERS + VIEWING TIME FOR VIRTUAL POSTERS**  
**CO-CHAIRS: DR. HARISSIOS VLIAGOFTIS, DR. ELINOR SIMONS, DR. CATHERINE BIGGS AND DR. SAMIRA JEIMY**
- 1500-1510**      **VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)**
- 1510-1530**      **PLENARY SESSION VII – ANAPHYLAXIS**  
**MODERATORS: DR. ANNE ELLIS AND DR. PHILIPPE BÉGIN**  
**1510-1530      SPEAKER: DR. WALEED ALQURASHI, OTTAWA**  
**TOPIC: CANADIAN ADVANCES IN ANAPHYLAXIS MANAGEMENT: TREKK IMPLEMENTATION AND NEW RECOMMENDATIONS ON STEROIDS**  
**OBJECTIVES: By the end of this session participants will be able to:**  
**1. Define TREKK**  
**2. Synthesize data on advances in anaphylaxis management**
- 1530-1540      DISCUSSION PERIOD**
- 1540-1600**      **CLOSING REMARKS BY DR. HAROLD KIM AND BY DR. TIM VANDER LEEK, NEW CSACI PRESIDENT**